A synthetic curcumin-like diarylpentanoid analog inhibits rhinovirus infection in H1 hela cells via multiple antiviral mechanisms.
Antiviral
Curcumin
Diarylpentanoid analog
Prophylactic
Rhinovirus
Virucidal
Journal
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
ISSN: 2008-2231
Titre abrégé: Daru
Pays: Switzerland
ID NLM: 101125969
Informations de publication
Date de publication:
12 Oct 2024
12 Oct 2024
Historique:
received:
20
03
2024
accepted:
19
09
2024
medline:
12
10
2024
pubmed:
12
10
2024
entrez:
12
10
2024
Statut:
aheadofprint
Résumé
Rhinovirus (RV) infection is a major cause of common colds and asthma exacerbations, with no antiviral drug available. Curcumin exhibits broad-spectrum antiviral activities, but its therapeutic effect is limited by a poor pharmacokinetics profile. Curcumin-like diarylpentanoid analogs, particularly 2-benzoyl-6-(3,4-dihydroxybenzylidene)cyclohexen-1-ol (BDHBC) and 5-(3,4-dihydroxyphenyl)-3-hydroxy-1-(2-hydroxyphenyl)penta-2,4-dien-1-one (DHHPD), have better solubility and stability compared to curcumin. Therefore, this study aims to evaluate and compare the antiviral effects of curcumin, BDHBC, and DHHPD in an in vitro model of RV infection. The inhibitory effects on RV-16 infection in H1 HeLa cells were assessed using cytopathic effect (CPE) reduction assay, virus yield reduction assay, RT-qPCR, and Western blot. Antiviral effects in different modes of treatment (pre-, co-, and post-treatment) were also compared. Additionally, intercellular adhesion molecule 1 (ICAM-1) expression, RV binding, and infectivity were measured with Western blot, flow cytometry, and virucidal assay, respectively. When used as a post-treatment, BDHBC (EC BDHBC exhibits multiple antiviral mechanisms against RV infection and thus could be a potential antiviral agent for RV.
Sections du résumé
BACKGROUND
BACKGROUND
Rhinovirus (RV) infection is a major cause of common colds and asthma exacerbations, with no antiviral drug available. Curcumin exhibits broad-spectrum antiviral activities, but its therapeutic effect is limited by a poor pharmacokinetics profile. Curcumin-like diarylpentanoid analogs, particularly 2-benzoyl-6-(3,4-dihydroxybenzylidene)cyclohexen-1-ol (BDHBC) and 5-(3,4-dihydroxyphenyl)-3-hydroxy-1-(2-hydroxyphenyl)penta-2,4-dien-1-one (DHHPD), have better solubility and stability compared to curcumin.
OBJECTIVES
OBJECTIVE
Therefore, this study aims to evaluate and compare the antiviral effects of curcumin, BDHBC, and DHHPD in an in vitro model of RV infection.
METHODS
METHODS
The inhibitory effects on RV-16 infection in H1 HeLa cells were assessed using cytopathic effect (CPE) reduction assay, virus yield reduction assay, RT-qPCR, and Western blot. Antiviral effects in different modes of treatment (pre-, co-, and post-treatment) were also compared. Additionally, intercellular adhesion molecule 1 (ICAM-1) expression, RV binding, and infectivity were measured with Western blot, flow cytometry, and virucidal assay, respectively.
RESULTS
RESULTS
When used as a post-treatment, BDHBC (EC
CONCLUSION
CONCLUSIONS
BDHBC exhibits multiple antiviral mechanisms against RV infection and thus could be a potential antiviral agent for RV.
Identifiants
pubmed: 39395148
doi: 10.1007/s40199-024-00542-x
pii: 10.1007/s40199-024-00542-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Higher Education Malaysia
ID : FRGS/1/2023/SKK15/UPM/02/3
Informations de copyright
© 2024. The Author(s), under exclusive licence to Tehran University of Medical Sciences.
Références
Jacobs SE, Lamson DM, Kirsten S, Walsh TJ. Human rhinoviruses. Clin Microbiol Rev. 2013;26(1):135–62.
pubmed: 23297263
pmcid: 3553670
doi: 10.1128/CMR.00077-12
Casanova V, Sousa FH, Stevens C, Barlow PG. Antiviral therapeutic approaches for human rhinovirus infections. Future Virol. 2018;13(7):505–18.
pubmed: 30245735
pmcid: 6136076
doi: 10.2217/fvl-2018-0016
McLean GR. Developing a vaccine for human rhinoviruses. J Vaccines Immun. 2014;2(3):16.
pubmed: 25593706
pmcid: 4291752
doi: 10.14312/2053-1273.2014-3
Feddema JJ, Claassen E. Prevalence of viral respiratory infections amongst asthmatics: Results of a meta-regression analysis. Respir Med. 2020;173:106020.
pubmed: 33190740
doi: 10.1016/j.rmed.2020.106020
Thomas BJ, Porritt RA, Hertzog PJ, Bardin PG, Tate MD. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci Reports. 2014;4(1):1–11.
Papi A, Contoli M, Adcock IM, Bellettato C, Padovani A, Casolari P, et al. Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor κb and c-Jun N-terminal kinase activation. J Allergy Clin Immunol. 2013;132(5):1075–85.
pubmed: 23871663
doi: 10.1016/j.jaci.2013.05.028
Edwards MR, Walton RP, Jackson DJ, Feleszko W, Skevaki C, Jartti T, et al. The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations. Allergy. 2018;73(1):50–63.
pubmed: 28722755
doi: 10.1111/all.13257
Egorova A, Kazakova E, Jahn B, Ekins S, Makarov V, Schmidtke M. Novel pleconaril derivatives: Influence of substituents in the isoxazole and phenyl rings on the antiviral activity against enteroviruses. Eur J Med Chem. 2020;188:112007.
pubmed: 31881489
doi: 10.1016/j.ejmech.2019.112007
Danov O, Lasswitz L, Obernolte H, Hesse C, Braun A, Wronski S, Sewald K. Rupintrivir reduces RV-induced TH-2 cytokine IL-4 in precision-cut lung slices (PCLS) of HDM-sensitized mice ex vivo. Respir Res. 2019;20:1–9.
doi: 10.1186/s12931-019-1175-y
Turner RB, Wecker MT, Pohl G, Witek TJ, McNally E, St. George R, et al. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA. 1999;281(19):1797–804.
pubmed: 10340366
doi: 10.1001/jama.281.19.1797
Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of the golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol. 2012;39(3):283.
pubmed: 22118895
pmcid: 3288651
doi: 10.1111/j.1440-1681.2011.05648.x
Chen DY, Shien JH, Tiley L, Chiou SS, Wang SY, Chang TJ, et al. Curcumin inhibits influenza virus infection and haemagglutination activity. Food Chem. 2010;119(4):1346–51.
doi: 10.1016/j.foodchem.2009.09.011
Dai J, Gu L, Su Y, Wang Q, Zhao Y, Chen X, et al. Inhibition of curcumin on influenza A virus infection and influenzal pneumonia via oxidative stress, TLR2/4, p38/JNK MAPK and NF-κB pathways. Int Immunopharmacol. 2018;54:177–87.
pubmed: 29153953
doi: 10.1016/j.intimp.2017.11.009
Han S, Xu J, Guo X, Huang M. Curcumin ameliorates severe influenza pneumonia via attenuating lung injury and regulating macrophage cytokines production. Clin Exp Pharmacol Physiol. 2018;45(1):84–93.
pubmed: 28853207
doi: 10.1111/1440-1681.12848
Lai Y, Yan Y, Liao S, Li Y, Ye Y, Liu N, et al. 3D-quantitative structure–activity relationship and antiviral effects of curcumin derivatives as potent inhibitors of influenza H1N1 neuraminidase. Arch Pharm Res. 2020;43(5):489–502.
pubmed: 32248350
pmcid: 7125423
doi: 10.1007/s12272-020-01230-5
Ou JL, Mizushina Y, Wang SY, Chuang DY, Nadar M, Hsu WL. Structure–activity relationship analysis of curcumin analogues on anti-influenza virus activity. FEBS J. 2013;280(22):5829–40.
pubmed: 24034558
doi: 10.1111/febs.12503
Xu Y, Liu L. Curcumin alleviates macrophage activation and lung inflammation induced by influenza virus infection through inhibiting the NF-κB signaling pathway. Influenza Other Respir Viruses. 2017;11(5):457–63.
pubmed: 28646616
pmcid: 5596526
doi: 10.1111/irv.12459
Obata K, Kojima T, Masaki T, Okabayashi T, Yokota S, Hirakawa S, et al. Curcumin prevents replication of respiratory syncytial virus and the epithelial responses to it in human nasal epithelial cells. PLoS ONE. 2013;8(9):e70225.
pubmed: 24058438
pmcid: 3776807
doi: 10.1371/journal.pone.0070225
Yang XX, Li CM, Li YF, Wang J, Huang CZ. Synergistic antiviral effect of curcumin functionalized graphene oxide against respiratory syncytial virus infection. Nanoscale. 2017;9(41):16086–92.
pubmed: 29034936
doi: 10.1039/C7NR06520E
Zhang C, Zhang K, Zang G, Chen T, Lu N, Wang S, et al. Curcumin inhibits replication of human parainfluenza virus type 3 by affecting viral inclusion body formation. Biomed Res Int. 2021;2021(1):1807293.
pubmed: 34409100
pmcid: 8367592
Wen CC, Kuo YH, Jan JT, Liang PH, Wang SY, Liu HG, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem. 2007;50(17):4087–95.
pubmed: 17663539
doi: 10.1021/jm070295s
Marín-Palma D, Tabares-Guevara JH, Zapata-Cardona MI, Flórez-álvarez L, Yepes LM, Rugeles MT, et al. Curcumin inhibits in vitro SARS-CoV-2 infection in vero E6 cells through multiple antiviral mechanisms. Molecules. 2021;26(22):6900.
pubmed: 34833991
pmcid: 8618354
doi: 10.3390/molecules26226900
Abidi A, Gupta S, Agarwal M, Bhalla HL, Saluja M. Evaluation of efficacy of curcumin as an add-on therapy in patients of bronchial asthma. J Clin Diagn Res. 2014;8(8):HC19.
pubmed: 25302215
pmcid: 4190737
Edin J, Mitja K, Nermina A, Jasmina N, Mona A-A, Azra J, et al. Curcumin improves step 4 asthma treatment: placebo-controlled, single blind study. Pulm Resp Med Int J. 2019;2(1):5–9.
Priyadarsini KI. The chemistry of curcumin: from extraction to therapeutic agent. Molecules. 2014;19(12):20091.
pubmed: 25470276
pmcid: 6270789
doi: 10.3390/molecules191220091
Górnicka J, Mika M, Wróblewska O, Siudem P, Paradowska K. Methods to improve the solubility of curcumin from turmeric. Life. 2023;13(1):207.
pubmed: 36676157
pmcid: 9862957
doi: 10.3390/life13010207
Noureddin SA, El-Shishtawy RM, Al-Footy KO. Curcumin analogues and their hybrid molecules as multifunctional drugs. Eur J Med Chem. 2019;182:111631.
pubmed: 31479974
doi: 10.1016/j.ejmech.2019.111631
Leong SW, Mohd Faudzi SM, Abas F, Mohd Aluwi MFF, Rullah K, Wai LK, et al. Synthesis and sar study of diarylpentanoid analogues as new anti-inflammatory agents. Molecules. 2014;19(10):16058–81.
pubmed: 25302700
pmcid: 6271425
doi: 10.3390/molecules191016058
Leong SW, Mohd Faudzi SM, Abas F, Mohd Aluwi MFF, Rullah K, Lam KW, et al. Nitric oxide inhibitory activity and antioxidant evaluations of 2-benzoyl-6-benzylidenecyclohexanone analogs, a novel series of curcuminoid anddiarylpentanoid derivatives. Bioorg Med Chem Lett. 2015;25(16):3330–7.
pubmed: 26071636
doi: 10.1016/j.bmcl.2015.05.056
Azmi F, Leong SW, Abas F, Ming OH, Perimal EK, Akira A, et al. Antinociceptive effect of 2-benzoyl-6-(3,4-dihydroxybenzylidene)cyclohexen-1-ol on nociception induced models in mice. J Pharmacol Toxicol Investig. 2016;2(1):1–9.
Kamarudin N, Hisamuddin N, Ong HM, Ahmad Azmi AF, Leong SW, Abas F, et al. Analgesic effect of 5-(3,4-Dihydroxyphenyl)-3-hydroxy-1-(2-hydroxyphenyl)penta-2,4-dien-1-one in experimental animal models of nociception. Molecules. 2018;23(9):2099.
pubmed: 30134576
pmcid: 6225497
doi: 10.3390/molecules23092099
Liew KY, Rosly NA, Abas F, Leong SW, Israf DA, Tham CL. Effect of diarylpentanoid analogues on lipopolysaccharide-induced interleukin-6 and interleukin-8 gene expression in airway inflammation. Malaysian J Med Heal Sci. 2019;15(SP2):10–7.
Rajan D, Gaston KA, McCracken CE, Erdman DD, Anderson LJ. Response to Rhinovirus infection by human airway epithelial cells and peripheral blood mononuclear cells in an in vitro two-chamber tissue culture system. PLoS One. 2013;8(6):e66600.
pubmed: 23799120
pmcid: 3684571
doi: 10.1371/journal.pone.0066600
Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938;27(3):493–7.
doi: 10.1093/oxfordjournals.aje.a118408
Ngan LTM, Jang MJ, Kwon MJ, Ahn YJ. Antiviral activity and possible mechanism of action of constituents identified in paeonia lactiflora root toward human rhinoviruses. PLoS ONE. 2015;10(4):e0121629.
pubmed: 25860871
pmcid: 4393083
doi: 10.1371/journal.pone.0121629
Zhou X, Zhu L, Lizarraga R, Chen Y. Human airway epithelial cells direct significant rhinovirus replication in monocytic cells by enhancing ICAM1 expression. Am J Respir Cell Mol Biol. 2017;57(2):216–25.
pubmed: 28328242
pmcid: 5576581
doi: 10.1165/rcmb.2016-0271OC
Aoki-Utsubo C, Chen M, Hotta H. Time-of-addition and temperature-shift assays to determine particular step(s) in the viral life cycle that is blocked by antiviral substance(s). Bio-protocol. 2018;8(9):e2830.
pubmed: 34286039
pmcid: 8275244
doi: 10.21769/BioProtoc.2830
Mercorelli B, Oreste P, Sinigalia E, Muratore G, Lembo D, Palù G, et al. Sulfated derivatives of escherichia coli K5 capsular polysaccharide are potent inhibitors of human cytomegalovirus. Antimicrob Agents Chemother. 2010;54(11):4561.
pubmed: 20713657
pmcid: 2976136
doi: 10.1128/AAC.00721-10
Denani CB, Real-Hohn A, de Carvalho CA, Gomes AM, Gonçalves RB. Lactoferrin affects rhinovirus B-14 entry into H1-HeLa cells. Arch Virol. 2021;166(4):1203–11.
pubmed: 33606112
pmcid: 7894240
doi: 10.1007/s00705-021-04993-4
Lee WM, Chen Y, Wang W, Mosser A. Growth of human rhinovirus in H1-HeLa cell suspension culture and purification of virions. Methods Mol Biol. 2015;1221:49–61.
pubmed: 25261306
doi: 10.1007/978-1-4939-1571-2_5
Smee DF, Hurst BL, Evans WJ, Clyde N, Wright S, Peterson C, et al. Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties. J Virol Methods. 2017;246:51.
pubmed: 28359770
pmcid: 5479350
doi: 10.1016/j.jviromet.2017.03.012
Müller JA, Harms M, Schubert A, Mayer B, Jansen S, Herbeuval JP, et al. Development of a high-throughput colorimetric Zika virus infection assay. Med Microbiol Immunol. 2017;206(2):175.
pubmed: 28176006
pmcid: 5357303
doi: 10.1007/s00430-017-0493-2
Takeuchi H, Baba M, Shigeta S. An application of tetrazolium (MTT) colorimetric assay for the screening of anti-herpes simplex virus compounds. J Virol Methods. 1991;33(1–2):61–71.
pubmed: 1658029
doi: 10.1016/0166-0934(91)90008-N
Esneau C, Bartlett N, Bochkov YA. Rhinovirus structure, replication, and classification. In: Elsevier eBooks [Internet]. 2019. p. 1–23. https://doi.org/10.1016/b978-0-12-816417-4.00001-9 .
doi: 10.1016/b978-0-12-816417-4.00001-9
Lee WM, Monroe SS, Rueckert RR. Role of maturation cleavage in infectivity of picornaviruses: activation of an infectosome. J Virol. 1993;67(4):2110.
pubmed: 8383233
pmcid: 240305
doi: 10.1128/jvi.67.4.2110-2122.1993
Ganjian H, Zietz C, Mechtcheriakova D, Blaas D, Fuchs R. ICAM-1 binding rhinoviruses enter HeLa cells via multiple pathways and travel to distinct intracellular compartments for uncoating. Viruses. 2017;9(4):68.
pubmed: 28368306
pmcid: 5408674
doi: 10.3390/v9040068
Rennolds J, Malireddy S, Hassan F, Tridandapani S, Parinandi N, Boyaka PN, et al. Curcumin regulates airway epithelial cell cytokine responses to the pollutant cadmium. Biochem Biophys Res Commun. 2012;417(1):256–61.
pubmed: 22142850
doi: 10.1016/j.bbrc.2011.11.096
Wieczfinska J, Sitarek P, Kowalczyk T, Rieske P, Pawliczak R. Curcumin modulates airway remodelling-contributing genes—the significance of transcription factors. J Cell Mol Med. 2022;26(3):736.
pubmed: 34939316
doi: 10.1111/jcmm.17102
Hassanzadeh K, Buccarello L, Dragotto J, Mohammadi A, Corbo M, Feligioni M. Obstacles against the marketing of curcumin as a drug. Int J Mol Sci. 2020;21(18):6619.
pubmed: 32927725
pmcid: 7554750
doi: 10.3390/ijms21186619
Basnet S, Palmenberg AC, Gern JE. Rhinoviruses and their receptors. Chest. 2019;155(5):1018–25.
pubmed: 30659817
pmcid: 6533451
doi: 10.1016/j.chest.2018.12.012
Suzuki T, Yamaya M, Sekizawa K, Yamada N, Nakayama K, Ishizuka S, Kamanaka M, Morimoto T, Numazaki Y, Sasaki H. Effects of dexamethasone on rhinovirus infection in cultured human tracheal epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2000;278(3):L560–71.
pubmed: 10710529
doi: 10.1152/ajplung.2000.278.3.L560
Anasir MI, Zarif F, Poh CL. Antivirals blocking entry of enteroviruses and therapeutic potential. J Biomed Sci. 2021;28(1):1–12.
doi: 10.1186/s12929-021-00708-8
Cagno V, Andreozzi P, D’Alicarnasso M, Silva PJ, Mueller M, Galloux M, et al. Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. Nat Mater. 2017;17(2):195–203.
pubmed: 29251725
doi: 10.1038/nmat5053
Amineva SP, Aminev AG, Gern JE, Palmenberg AC. Comparison of rhinovirus A infection in human primary epithelial and HeLa cells. J Gen Virol. 2011;92(11):2549.
pubmed: 21752966
pmcid: 3352362
doi: 10.1099/vir.0.031302-0
Coultas JA, Cafferkey J, Mallia P, Johnston SL. Experimental antiviral therapeutic studies for human rhinovirus infections. J Exp Pharmacol. 2021;13:645–59.
pubmed: 34276229
pmcid: 8277446
doi: 10.2147/JEP.S255211
Bartlett NW, Walton RP, Edwards MR, Aniscenko J, Caramori G, Zhu J, Glanville N, Choy KJ, Jourdan P, Burnet J, Tuthill TJ. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med. 2008;14(2):199–204.
pubmed: 18246079
pmcid: 3384678
doi: 10.1038/nm1713
Santos MMM, Moreira R. Michael acceptors as cysteine protease inhibitors. Mini-Rev Med Chem. 2007;7(10):1040–50.
pubmed: 17979807
doi: 10.2174/138955707782110105
Wang QM, Johnson RB, Jungheim LN, Cohen JD, Villarreal EC. Dual inhibition of human rhinovirus 2A and 3C proteases by homophthalimides. Antimicrob Agents Chemother. 1998;42(4):916.
pubmed: 9559808
pmcid: 105567
doi: 10.1128/AAC.42.4.916